183 related articles for article (PubMed ID: 36565131)
1. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.
McDonald CM; Mayer OH; Hor KN; Miller D; Goemans N; Henricson EK; Marden JR; Freimark J; Lane H; Zhang A; Frean M; Trifillis P; Koladicz K; Signorovitch J;
J Neuromuscul Dis; 2023; 10(1):67-79. PubMed ID: 36565131
[TBL] [Abstract][Full Text] [Related]
2. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids.
Schiava M; Lofra RM; Bourke JP; Díaz-Manera J; James MK; Elseed MA; Malinova M; Michel-Sodhi J; Moat D; Ghimenton E; Mccallum M; Díaz CFB; Mayhew A; Wong K; Richardson M; Tasca G; Eglon G; Eagle M; Turner C; Heslop E; Straub V; Bettolo CM; Guglieri M
Eur J Neurol; 2024 Jun; 31(6):e16267. PubMed ID: 38556893
[TBL] [Abstract][Full Text] [Related]
3. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
[No Abstract] [Full Text] [Related]
6. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
7. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
[No Abstract] [Full Text] [Related]
8. Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials.
McDonald CM; Signorovitch J; Mercuri E; Niks EH; Wong B; Fillbrunn M; Sajeev G; Yim E; Dieye I; Miller D; Ward SJ; Goemans N;
PLoS One; 2024; 19(6):e0304099. PubMed ID: 38829874
[TBL] [Abstract][Full Text] [Related]
9. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
10. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
Wong BL; Cook T; Miller H
J Comp Eff Res; 2022 Aug; 11(11):779-786. PubMed ID: 35713895
[TBL] [Abstract][Full Text] [Related]
11. Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids.
Abutaleb ARA; McNally EM; Khan SS; Anderson AS; Carr JC; Wilcox JE
JAMA Cardiol; 2018 Oct; 3(10):1006-1010. PubMed ID: 30167630
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
[TBL] [Abstract][Full Text] [Related]
13. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Bourke JP; Bueser T; Quinlivan R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
[TBL] [Abstract][Full Text] [Related]
14. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.
Ricotti V; Selby V; Ridout D; Domingos J; Decostre V; Mayhew A; Eagle M; Butler J; Guglieri M; Van der Holst M; Jansen M; Verschuuren JJGM; de Groot IJM; Niks EH; Servais L; Straub V; Voit T; Hogrel JY; Muntoni F
Neuromuscul Disord; 2019 Apr; 29(4):261-268. PubMed ID: 30852071
[TBL] [Abstract][Full Text] [Related]
15. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
[No Abstract] [Full Text] [Related]
16. The Association between the Respiratory System and Upper Limb Strength in Males with Duchenne Muscular Dystrophy: A New Field for Intervention?
Sobierajska-Rek A; Wasilewska E; Śledzińska K; Jabłońska-Brudło J; Małgorzewicz S; Wasilewski A; Szalewska D
Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497753
[TBL] [Abstract][Full Text] [Related]
17. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.
Tandon A; Villa CR; Hor KN; Jefferies JL; Gao Z; Towbin JA; Wong BL; Mazur W; Fleck RJ; Sticka JJ; Benson DW; Taylor MD
J Am Heart Assoc; 2015 Mar; 4(4):. PubMed ID: 25814625
[TBL] [Abstract][Full Text] [Related]
18. The Performance of the Upper Limb scores correlate with pulmonary function test measures and Egen Klassifikation scores in Duchenne muscular dystrophy.
Lee HN; Sawnani H; Horn PS; Rybalsky I; Relucio L; Wong BL
Neuromuscul Disord; 2016; 26(4-5):264-71. PubMed ID: 27056113
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
[TBL] [Abstract][Full Text] [Related]
20. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.
Angelini C; Peterle E
Acta Myol; 2012 May; 31(1):9-15. PubMed ID: 22655511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
